It is hard to satisfy this market, but you can’t start a trial without an approval, and the company has gotten two approvals and will start the trials. Once they begin, tutes will start buying. Rett is important, but it seems the company wants to get an approval with a single shot. This is actually good in the long run (hoping that science works). FDA’s continued back and forth makes me think they like what they have seen so far but are asking for a better design..
Market Data 
Markets 
AI
